In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Multaq (Sanofi-Aventis)
- INDICATIONS: Atrial fibrillation and atrial flutter
- CLASS: Antiarrhythmic, Antiarrhythmic class III
- HALF-LIFE: 13–19 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Amitriptyline, Amoxapine, Antiarrhythmics, Antipsychotics prolonging QT interval, Arsenic, Atorvastatin, Beta blockers, Bupivacaine, Calcium channel blockers, Carbamazepine, Citalopram, Clarithromycin, Conivaptan, Coumarins, Cyclosporine, CYP3A inducers, Dabigatran, Darunavir, Dasatinib, Degarelix, Delavirdine, Digoxin, Diltiazem, Disopyramide, Dolasetron, Efavirenz, Erythromycin, Fingolimod, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Levobupivacaine, Levofloxacin, Levomepromazine, Metoprolol, Moxifloxacin, Nefazodone, Neratinib, Nifedipine, Ombitasvir/Paritaprevir/Ritonavir, Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir, Oxcarbazepine, Pazopanib, Phenindione, Phenobarbital, Phenothiazines, Phenytoin, Posaconazole, Prilocaine, Propranolol, Rifampin, Rifapentine, Ritonavir, Ropivacaine, Rosuvastatin, Saquinavir, Simvastatin, Sirolimus, Sotalol, St John's Wort, Statins, Tacrolimus, Telavancin, Telithromycin, Tricyclic antidepressants, Venetoclax, Verapamil, Voriconazole, Vorinostat, Warfarin, Ziprasidone
- See adverse reactions attributed to class:
INCREASED RISK OF DEATH, STROKE AND HEART FAILURE IN PATIENTS WITH DECOMPENSATED HEART FAILURE OR PERMANENT ATRIAL FIBRILLATION
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of dronedarone in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
